Pharmacogenomic potential in advanced cancer patients

Dan Nichols, Susanne Arnold, Heidi L. Weiss, Jianrong Wu, Eric B. Durbin, Rachel Miller, Jill Kolesar

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Purpose. The prevalence of pharmacogenetically actionable medications in advanced cancer patients whose therapy may be optimized with genotype data was determined. Methods. Patients enrolled in our institutional molecular tumor board observational cohort were included in this study. Collected data included demographics, type(s) of cancer, and outpatient medications. Medications were classified as "pharmacogenetically actionable" if there are Clinical Pharmacogenetics Implementation Consortium (CPIC) therapeutic recommendations for that medication based on the presence of germline variations. The prevalence of pharmacogenetically actionable medications in the study population was determined, and the frequency of opportunities for pharmacogenetic prescribing and adverse event (AE) mitigation were estimated. Results. In a cohort of 193 patients with advanced cancer, 65% of patients were taking a pharmacogenetically actionable medication. Approximately 10% of the outpatient medications taken by the study population had a pharmacogenetic association. The most common pharmacogenetically actionable medications being used were ondansetron (47%), capecitabine (10%), and sertraline (7%). Using published genetic variation frequencies and AE risk, we conservatively estimated that 7.1% of cancer patients would be eligible for genetic-based medication adjustment, and 101 AEs would be prevented in 10,000 patients genotyped. Conclusion. Medications with pharmacogenetic associations are used commonly in the advanced cancer patient population. This widespread exposure supports the implementation of prospective genotyping in the treatment of these high-risk patients.

Original languageEnglish
Pages (from-to)415-423
Number of pages9
JournalAmerican Journal of Health-System Pharmacy
Volume76
Issue number7
DOIs
StatePublished - Mar 19 2019

Keywords

  • Cancer
  • germline
  • oncology
  • pharmacogenetics
  • pharmacogenomics

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Fingerprint

Dive into the research topics of 'Pharmacogenomic potential in advanced cancer patients'. Together they form a unique fingerprint.

Cite this